Alembic Pharmaceuticals Limited (NSE: APLLTD) announced its financial results for the quarter ended June 30, 2026, on August 4, 2026, alongside a previously recommended final dividend of ₹12 per equity share for FY26, as approved by the Board of Directors on May 15, 2026. The dual announcements mark a continued focus on shareholder returns even as the mid-cap pharmaceutical company navigates a competitive generics landscape.

Dividend Details and Year-on-Year Comparison

The FY26 final dividend of ₹12 per share represents a 9.1% increase over the ₹11 per share paid in FY25 and the identical ₹11 per share declared in FY24. The face value of APLLTD shares is ₹2, making this a 600% dividend on face value. With trade data unavailable at the time of publishing, a precise dividend yield calculation requires referencing the current market price against the ₹12 per share payout; investors should note that at a hypothetical price of ₹1,000, the yield would stand at 1.2%, rising to approximately 1.6% at ₹750.

Historical Dividend Trend Analysis

A review of Alembic Pharmaceuticals' dividend history over the past seven years reveals a clear trajectory with one notable dip:

The data shows that after the company scaled back payouts significantly in FY23 — likely reflecting margin pressure from elevated US generics competition and domestic pricing headwinds — distributions have recovered steadily over the last three fiscal years. The FY26 dividend is now the highest single final dividend since FY22's interim payout and surpasses the standalone FY21 final of ₹14 only when accounting for face value adjustments and payout context.

Q1 FY27 Results Context

The Board meeting held on August 4, 2026, produced two separate exchange filings: one confirming the outcome of the board meeting and a second specifically submitting the financial results for the period ended June 30, 2026, to NSE. The detailed Q1 FY27 numbers, including revenue, EBITDA margins, and net profit, were submitted via the results filing at 14:10 IST. Alembic Pharmaceuticals derives revenues from domestic branded formulations, international generics including the US market, and active pharmaceutical ingredients, making quarterly performance sensitive to US FDA inspection outcomes and currency movements.

What This Means for Investors

The ₹12 per share dividend signals that the company's board retains confidence in its cash generation capacity heading into FY27. For income-oriented investors, the steady recovery in per-share payouts from the FY23 trough of ₹8 to the current ₹12 is a positive signal, reflecting a compound annual growth rate of approximately 14.5% in dividend per share over three years. However, the absence of an interim dividend in FY26, unlike the dual-dividend structure seen in FY22, means total annual shareholder returns through dividends remain below that peak year. Investors tracking APLLTD should monitor the detailed Q1 FY27 results for margin trends and US business momentum, as these will determine whether the dividend growth trajectory can be sustained into FY27.